[{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics and NYSCF File Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$775.0 million","upfrontCash":"$15.0 million","newsHeadline":"Cytovia Therapeutics and Cellectis Partner to Develop TALEN\u00ae Gene-Edited iPSC-Derived Natural Killer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"TF Capital","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoLynx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$400.0 million","newsHeadline":"Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture to Advance NK Cell Therapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovia and Cellectis Expand Their TALEN\u00ae Gene-Edited iNK Partnership to Enable Broader Collaboration in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK Engager Multispecific Antibodies at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK\u2122 Cell Engagers at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Isleworth Healthcare Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"$20.0 million","newsHeadline":"Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics Presents Antitumor Activity of Its Cd38-targeting FLEX-NK\u2122 Cell Engager Antibody at EHA 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics To Present New Data on CD38 Flex-NK\u2122 Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"$20.0 million","newsHeadline":"Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Cytovia Therapeutics
Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates.
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activation receptor NKp46.
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46.
Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s):
iPSC-derived NK Cells,Flex-NK Cell Engager
In addition, CYT-503, a GPC3-targeting CAR-iNK cell therapeutic, is designed to improve specificity for tumor targeting. Cytovia expects to file INDs for CYT-303 and CYT-100, followed by INDs for CYT-150 and CYT-503.
Lead Product(s):
iPSC-derived NK Cells,Flex-NK Cell Engager
First in vivo data demonstrated anti-tumor activity of Glypican-3 (GPC3) Flex-NK™ cell engager CYT-303 in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC).
CYT 303 is a FLEX-NK® tetravalent bispecific trifunctional antibody targeting GPC3, a glycoprotein highly expressed on solid tumors, including Hepatocellular carcinoma, but not on adult healthy cells, is being developed to treat solid tumors expressing GPC3, including HCC.
Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s):
Gene-edited iPSC-derived NK cells
TF Capital, a leading China-based biotech institutional investor and Cytovia have formed CytoLynx Therapeutics, and invests to finance the IND enabling and initial clinical development of the pipeline programs including CYT-303.
CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization including CYT-100.